<DOC>
	<DOC>NCT03056989</DOC>
	<brief_summary>Ascending dose, 7-day, open label safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.</brief_summary>
	<brief_title>A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Confirmed diagnosis of CF FEV1 â‰¥ 40% predicted normal Stable CF lung disease Nonpregnant, nonlactating females Significant unstable comorbidities within 28 days of screening as judged by the Investigator. Has received an investigational drug within the past 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>